Login / Signup

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab.

Ashish SrinivasanCraig HaiferLena Thin
Published in: The Medical journal of Australia (2021)
Keyphrases
  • ulcerative colitis
  • high intensity
  • early onset
  • drug induced